Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M412Revenue (TTM) $M26.8Net Margin (%)-376.2Altman Z-Score-4.5
Enterprise Value $M382EPS (TTM) $-1.2Operating Margin %-336.9Piotroski F-Score3
P/E(ttm)--Beneish M-Score-1.4Pre-tax Margin (%)-396.3Higher ROA y-yN
Price/Book9.210-y EBITDA Growth Rate %-23.8Quick Ratio5.2Cash flow > EarningsY
Price/Sales14.35-y EBITDA Growth Rate %0.4Current Ratio5.2Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-50.3Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-155.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M86.9ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with AGEN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AGENKen Fisher 2015-09-30 Buy $4.43 - $9.44
($7.57)
$ 4.74-37%New holding91,632
AGENFirst Eagle Investment 2014-06-30 Sold Out -0.0017%$2.41 - $3.61
($2.94)
$ 4.7461%Sold Out0
AGENGeorge Soros 2014-06-30 Sold Out $2.41 - $3.61
($2.94)
$ 4.7461%Sold Out0
AGENGeorge Soros 2014-03-31 Buy $2.64 - $5.1
($3.52)
$ 4.7435%New holding102,200
AGENFirst Eagle Investment 2014-03-31 Buy $2.64 - $5.1
($3.52)
$ 4.7435%New holding200,000
AGENRobert Bruce 2012-06-30 Buy 0.52%$4.84 - $6.9
($5.78)
$ 4.74-18%New holding233,515
AGENRobert Bruce 2010-12-31 Buy $5.34 - $6.48
($5.71)
$ 4.74-17%New holding233,517
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AGEN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AGEN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ARMEN GARO HChairman & CEO 2016-05-09Buy100,000$3.1850.31view
ARMEN GARO HChairman & CEO 2016-05-09Buy100,000$3.1850.31view
Baysal OzerChief Business Officer 2016-05-05Buy2,250$3.154.19view
ARMEN GARO HChairman & CEO 2016-03-07Buy200,000$4.0318.61view
ARMEN GARO HChairman & CEO 2015-12-29Sell219,576$4.594.14view
ARMEN GARO HChairman & CEO 2015-09-25Buy100,000$5.03-4.97view
Ballantyne Charles EvanCFO 2015-09-25Buy10,000$5.05-5.35view
Malik ShahzadDirector 2015-04-29Sell1,107,377$7.11-32.77view
QVT Associates GP LLC10% Owner 2015-01-09Sell2,343,630$5.31-9.98view
Wentworth KerryVP, Clinical, Reg & Qual 2014-02-26Sell5,000$5-4.4view

Quarterly/Annual Reports about AGEN:

News about AGEN:

Articles On GuruFocus.com
Weekly CEO Buys Highlights Mar 14 2016 
Paul Tudor Jones' Highest Performing Stocks Jul 13 2015 
Agenus Inc.: Ingeniously Designed Vaccines To Galvanized Tomorrow's Medicine Jul 25 2014 
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
Weekly CEO Buys Highlight: CTAS, VRX, TAT, AGEN, MRK Aug 20 2011 
Chairman & CEO of Agenus Inc. (AGEN) Garo Armen Buys 2,150,976 Shares Aug 18 2011 
Antigenics Inc. Reports Operating Results (10-K) Mar 16 2011 
Antigenics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 1,500 Shares Oct 28 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 2,000 Shares Sep 14 2010 

More From Other Websites
Agenus to Report Second Quarter 2016 Financial Results on July 28, 2016; Conference Call to Follow Jul 21 2016
AGENUS INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 19 2016
AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 06 2016
Agenus Appoints Jean-Marie Cuillerot, M.D. as Vice President and Global Head of Clinical Development Jul 06 2016
Agenus Appoints Jean-Marie Cuillerot, M.D. as Vice President and Global Head of Clinical Development Jul 06 2016
Agenus, Inc. breached its 50 day moving average in a Bearish Manner : AGEN-US : June 28, 2016 Jun 28 2016
Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody... Jun 22 2016
Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody... Jun 22 2016
AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 22 2016
Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody... Jun 22 2016
Agenus Charts Shows Upside Potential Jun 20 2016
AGENUS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Financial... Jun 16 2016
Agenus to Present at the 2016 JMP Securities Life Sciences Conference Jun 15 2016
Agenus to Present at the 2016 JMP Securities Life Sciences Conference Jun 15 2016
Agenus, Inc. breached its 50 day moving average in a Bearish Manner : AGEN-US : June 15, 2016 Jun 15 2016
Agenus Announces Lead Product Candidate Selection in its Collaboration with Merck Jun 09 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)